Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 2026 and completed on the same day. Consideration for the deal was provided in the form of shares. Neither the buyer nor the target is based outside the United States, indicating a domestic transaction between two US entities. The financial value of the acquisition was not disclosed to the public, and no specific currency was reported. This structure suggests a focus on equity exchange rather than cash payment, which is common in deals where valuation is complex or parties prefer shared long-term interest. The deal brings together two companies operating in the same national market, potentially consolidating capabilities within the US healthcare landscape. The completion date aligns with the announcement, implying a swift execution with minimal regulatory or operational hurdles during the integration phase.

The transaction has been successfully completed. All necessary steps to finalise the acquisition have been undertaken, and Cy Biopharma, Inc. is now part of Ensysce Biosciences, Inc. The deal marks the end of Cy Biopharma’s independent status as it integrates into the larger organisation. Shareholders of the target company have received their consideration in the form of Ensysce shares. There are no pending regulatory approvals or outstanding conditions mentioned in the available data. The completion signifies that both parties have fulfilled their contractual obligations. The integration process is now underway as the two entities combine their operations. This acquisition represents a significant step in the strategic growth of Ensysce Biosciences within the healthcare sector. The deal structure and execution reflect a straightforward approach to expanding the buyer’s portfolio through equity-based consideration.